Drug Database
GL

glimepiride + metformin (HOE490 O / HOE4900 / Amaryl M IR)

✓ Approved

Sanofi S.A · KCNJ11 · 小分子

什么是 glimepiride + metformin?

glimepiride + metformin 是一种小分子,由Sanofi S.A研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名HOE490 O, HOE4900, Amaryl M IR
公司Sanofi S.A
药物类别小分子
分子靶点KCNJ11, ABCC8
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

glimepiride + metformin 作用于 2 个分子靶点:

KCNJ11potassium inwardly rectifying channel subfamily J member 11 (BIR, HHF2)
ABCC8ATP binding cassette subfamily C member 8 (MRP8, SUR1delta2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

glimepiride + metformin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedBMC urology2026-11-18

Association of metformin use with metabolic trajectories and disease progression in prostate cancer patients receiving androgen deprivation therapy: a target trial emulation study.

He Yongkai Y, Tang Liang L, Yuan Kun K, Liu HuiYing H et al.

Androgen deprivation therapy (ADT) is associated with substantial metabolic deterioration in patients with prostate cancer. Metformin may attenuate ADT-related metabolic complications, although its association with longitudinal metabolic trajectories and prostate cancer outcomes remains uncertain. We conducted a retrospective cohort study emulating a target trial using a 90-day landmark design. Patients with prostate adenocarcinoma initiating ADT between 2015 and 2020 were classified according to metformin exposure during the landmark window (T₀ = Day 90 after ADT initiation). Metformin users initiated and maintained metformin treatment for at least 90 days, whereas controls had no metformin exposure. IPTW was applied to balance baseline characteristics. Longitudinal metabolic outcomes were assessed using weighted linear mixed-effects models, and progression outcomes were analyzed using weighted Cox models. Among 823 screened patients, 342 were included in the final analysis (171 metformin users and 171 controls). After IPTW adjustment, baseline covariates were well balanced. Compared with controls, metformin exposure was associated with smaller increases in HbA1c (adjusted difference - 0.34%, 95% CI - 0.58 to - 0.10) and triglycerides (- 26 mg/dL, 95% CI - 46 to - 6) during follow-up. Metformin exposure was also associated with lower observed risks of PSA progression (HR 0.71, 95% CI 0.52-0.96) and CRPC progression (HR 0.67, 95% CI 0.47-0.95), although these findings were considered exploratory because of limited event numbers. Metformin exposure was associated with less ADT-related metabolic deterioration and lower observed progression rates. These findings do not establish an anticancer effect and require confirmation in randomized studies.

PMID 43046007
阅读全文 →
PubMedBehavioural brain research2026-11-18

Metformin Preserves Hippocampal and Prefrontal Synaptic Integrity in Rats with Spinal Cord Injury: SIRT1 Induction and microRNA Modulation.

Kandemir Turan T, Ergen Fulya Büge FB, Coşan Didem Turgut DT, Özkara Emre E et al.

Spinal cord injury (SCI) is associated with memory-related behavioral deficits and dendritic alterations in supraspinal brain regions. We investigated whether metformin improves recognition-related behavior after SCI and examined accompanying structural and molecular changes. Adult female rats underwent clip-compression SCI and received daily intraperitoneal saline or metformin (50mg/kg) for 7 or 14 days; unoperated rats served as controls. Behavioral assessments included novel object recognition (NOR), Basso-Beattie-Bresnahan (BBB) locomotor scoring, and elevated plus maze (EPM) closed-arm-entry latency as an activity-related measure. Nissl and Golgi-Cox staining evaluated neuronal density and dendritic morphology in the hippocampus and prefrontal cortex. Hippocampal gene expression and protein concentrations were assessed using quantitative PCR and ELISA. NOR acquisition indices were similar across groups, whereas NOR discrimination was lower in saline-treated SCI rats than in controls at both time points. Metformin increased NOR discrimination versus saline at 14 days (p < 0.0001), but not at 7 days, and improved BBB recovery in both cohorts (p < 0.0001). EPM closed-arm-entry latency was shorter with metformin at both time points (p < 0.001). At 14 days, metformin-treated rats showed higher dendritic spine density in the prefrontal cortex and hippocampal CA1 (both p < 0.0001), higher hippocampal sirtuin 1 and brain-derived neurotrophic factor protein concentrations, and lower miR-132, miR-134, miR-138, and Rock1 expression than saline-treated SCI rats. Metformin was associated with improved recognition-related behavioral performance and locomotor recovery following SCI, accompanied by preservation of dendritic spine density and alterations in hippocampal plasticity-related markers.

PMID 43051322
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Comparison of the Efficacy of Kligman's Formula Combined With 30% Topical Metformin Versus Kligman's Formula Alone in the Treatment of Melasma.

Iraji Fariba F, Mokhtari Fatemeh F, Kassab Zeinab Z, Seyedyousefi Sarah S et al.

Melasma is a common hyperpigmentation disorder primarily affecting women, influenced by ultraviolet exposure, hormones, and genetics. Kligman's formula is a first-line therapy, but emerging evidence suggests that topical metformin, an antidiabetic with antimelanogenic effects, may enhance treatment outcomes. The objective of this study is to compare the efficacy and safety of Kligman's formula with and without 30% topical metformin in bilateral facial melasma. In this randomized, double-blind, split-face clinical trial, 31 patients with symmetrical facial melasma applied Cream A (Kligman's formula + 30% metformin) to one side and Cream B (Kligman's formula alone) to the other for 2 months. Outcomes included MASI scores, repigmentation grading, patient satisfaction via Visual Analog Scale (VAS), and side effect profiles assessed at baseline, post-treatment, and 2 months after discontinuation. Both treatments significantly reduced pigmentation and improved homogeneity. Cream B showed a slightly greater reduction in darkness, while Cream A led to more stable repigmentation and fewer cases of post-inflammatory hyperpigmentation. No significant differences were found between post-treatment and follow-up scores. VAS scores indicated high patient satisfaction across both groups. Adding 30% topical metformin to Kligman's formula is safe and comparably effective in melasma treatment, offering potential benefits in pigment stability and reduced PIH. Although differences were not statistically significant, clinical trends support further investigation through larger, long-term studies. ClinicalTrials.gov identifier: IRCT20150706023081N2.

PMID 43047029
阅读全文 →
PubMedMayo Clinic proceedings2026-11-18

SGLT2 Inhibitors Versus Metformin as First-Line Therapy for Cardiorenal Outcomes: A Target Trial Emulation Among New Users With Type 2 Diabetes.

Kung Fang-Ping FP, Tsai Ching-Fang CF, Chang Yu-Tzu YT

To compare cardiorenal and mortality outcomes associated with initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors versus metformin as first-line glucose-lowering therapy among new users with type 2 diabetes. Using a target trial emulation design with TriNetX Global Collaborative Network data, we identified adults (≥18 years) with type 2 diabetes who were new users of SGLT2 inhibitors or metformin from January 1, 2018, through December 31, 2023, with follow-up through June 10, 2025. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included individual MACE components, major adverse kidney events (MAKE), acute heart failure, all-cause mortality, and kidney failure requiring kidney replacement therapy. Propensity-score matching yielded 36,720 pairs. Over median follow-up of 2.5 and 3.5 years in the SGLT2 inhibitor and metformin groups, respectively, SGLT2 inhibitor initiation was associated with lower risks of MACE (HR, 0.88; 95% CI, 0.84-0.92), all-cause mortality (HR, 0.73; 95% CI, 0.68-0.77), stroke (HR, 0.84; 95% CI, 0.79-0.90), cardiac arrest (HR, 0.81; 95% CI, 0.68-0.95), and acute heart failure (HR, 0.94; 95% CI, 0.92-0.97). Myocardial infarction risk was similar between groups (HR, 0.97; 95% CI, 0.91-1.04). Kidney failure requiring kidney replacement therapy also did not differ significantly between groups (HR, 1.00; 95% CI, 0.87-1.14). Among new users with type 2 diabetes, first-line SGLT2 inhibitor initiation was associated with lower risks of MACE and all-cause mortality than metformin, while the risk of kidney failure requiring kidney replacement therapy was similar between groups.

PMID 43051408
阅读全文 →
PubMedFrontiers in immunology2026-11-18

Semaglutide and optic neuritis in the FDA adverse event reporting system: a comparator-based, time-calibrated pharmacovigilance analysis.

Xu Fengjiao F, Luo Wei W, Liu Zhuoran Z, Zhang Ran R et al.

Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists are increasingly used for glycemic control, obesity management, cardiovascular risk reduction, and kidney protection. Ocular safety research has focused mainly on diabetic retinopathy and nonarteritic anterior ischemic optic neuropathy. Whether inflammatory neuro-ophthalmic events, particularly optic neuritis, show a reproducible postmarketing reporting association remains uncertain. We performed a case/non-case pharmacovigilance study using FAERS reports from 2004Q1 to 2026Q1. Reports were deduplicated by CASEID/CASEVERSION. Primary-suspect GLP-1/GIP exposures were linked to MedDRA-defined inflammatory neuro-ophthalmic outcomes. The primary comparison was semaglutide versus SGLT2 inhibitors/metformin, with secondary DPP-4 inhibitor, strict non-GLP-1 weight-loss, separate SGLT2 inhibitor, separate metformin, and indication-restricted analyses. We used ROR, PRR, transparently labeled approximate shrinkage proxies, BH-FDR adjustment, exact report-year stratification, exact-year frequency matching, reporter-channel sensitivity, and Firth-type adjusted logistic regression. After latest-version deduplication, 59,790 semaglutide and 178,670 pooled SGLT2 inhibitor/metformin reports were included. The crude semaglutide-optic neuritis ROR was 11.67 (60 vs 15 events; 95% CI 6.68-20.40; BH q=1.99e-27). Given the different report-year distributions (semaglutide: 62.7% in 2024-2026; pooled comparator: 17.5%), the principal calendar-time-calibrated estimate was the exact report-year Mantel-Haenszel common OR of 5.06 (95% CI 2.64-9.72), supported by exact-year 1:1 frequency matching (OR 4.64, 95% CI 2.42-8.90). Separate comparator analyses remained positive for SGLT2 inhibitors (ROR 15.68, 95% CI 6.55-37.53) and metformin (ROR 8.53, 95% CI 4.43-16.42), whereas the obesity/weight-management restriction was sparse and not supported. Estimates were positive in health-professional and consumer/legal reports. The Firth-type adjusted OR was 16.76 (95% CI 8.51-33.00). Among 12 reports with valid TTO, the median was 62.5 days; TTO was analyzed descriptively without hazard modeling and did not support an early-failure or temporal causal inference. FAERS data support a semaglutide-optic neuritis reporting association that persists after calendar-time calibration and comparator expansion, but the magnitude is sensitive to reporting era and unmeasured clinical heterogeneity. The finding is hypothesis-generating, cannot establish incidence, relative risk, or causality, and should not be interpreted as complete separation from ischemic optic neuropathy/NAION. The sparse TTO subset was descriptive only and did not support an early-failure or temporal causal interpretation.

PMID 43047309
阅读全文 →
PubMedJournal of primary care & community health2026-11-18

Physicians' Prescribing Preferences for the Usage of Anti-Diabetic and Anti-Obesity Medications for Effective Weight Management in Iraq.

Ibrahim Albaroodi Khansaa A KA

PurposeThere is limited data on weight management medications in Iraq; therefore, this pilot study aimed to assess physicians' prescribing preferences for anti-diabetic and anti-obesity to support effective weight management.MethodsThis pilot study targeted healthcare professionals working in weight-loss clinics in Iraq; participants from four provinces: Karbala, Najaf, Diwaniya, and Hilla were included. Conducted between October 1, 2024, and December 31, 2024. The study used convenience sampling. Results were obtained by using SPSS (version 20).ResultsAmong 15 participants aged 44.6±8.3 years (ranging from 29 to 60 years), with 7.6±3.6 years (ranging from 2 to 14 years) of experience in nutrition, approximately 40% preferred either metformin or orlistat. Side effects that restricted medication use were nausea, dizziness, and diarrhea, with 40%, 33.3%, and 20%, respectively. All medication were assessed preference items on a dichotomous (yes/no) scale. No multi-item scale was used; therefore, range-based interpretation is not applicable. Preferences are reported as percentages of participants selecting each medication. No significant associations were observed between medications and comorbidities, except that semaglutide preference was positively associated with consideration of general health factors (Cramér's V = 1.000, p = 0.0001), indicating a strong effect size despite the small sample. No statistically significant difference in preference frequency was observed between metformin and orlistat (p = 0.132). Preference for semaglutide was not significantly lower than for metformin (p = 0.486, Fisher's exact test).ConclusionThis pilot study highlights obesity management and the need for transitioning from a weight-centric model to a comprehensive metabolic health framework. In practical terms, this includes routine comorbidity assessment before prescribing, using GLP-1 agonists for patients with obesity and cardiovascular risk factors, and insurance or subsidy policies to improve access to newer agents. As a pilot study with a small convenience sample (n=15), findings are preliminary and require validation in larger, multi-region Iraqi samples.

PMID 43050597
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多glimepiride + metformin